Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

Abstract

Patients with RT demonstrate promising signs of antitumor activity after multiagent relapse therapy including decitabine. Analyses of methylation data suggest a specific effect on an epigenetic level. We propose to consider decitabine and other epigenetic drugs as candidates for further clinical investigations in RT.